Recent News

and/or

17 News Items found

Roundup

Advances in Myeloma, Lymphoma, and Bone Marrow Transplant Announced at the 2018 ASH Meeting

Learn more about the work of MSK researchers being presented at the 2018 meeting of the American Society of Hematology.

ASH meeting signage

In the Lab

Why Do Immune Checkpoint Inhibitors Work for Only Some People with Cancer?

Learn about why checkpoint inhibitors, a class of immunotherapy drugs, 
is paying off — but only for some patients.

MSK physician­scientist Luis Diaz

In the Clinic

FDA Grants Breakthrough Therapy Designation to Omburtamab for Metastatic Neuroblastoma

A drug created at MSK called burtomab reaches an important milestone toward becoming a treatment for metastatic neuroblastoma.

MSK pediatric oncologist and neuroblastoma expert Kim Kramer

In the Clinic

The Science Behind the FDA’s Approval of an Immunotherapy for Mismatch Repair–Deficient Cancers

A new paper from MSK physician-scientist Luis Diaz presents the evidence on which the FDA approved the immunotherapy drug pembrolizumab for cancers with a specific genetic abnormality.

MSK medical oncologist Luis Diaz, Jr.

Feature

With MSK Leading the Way, Precision Medicine Links Lab Research to Patient Care

Therapies that target genetic alterations in tumors are showing promise for many cancer patients, but challenges in developing these new treatments remain.

In the News

Between the Moon and New York City: Vice President Biden Leads MSK Cancer Moonshot Roundtable

Find out what Vice President Joe Biden had to say when he visited MSK for a roundtable “cancer moonshot” discussion.

Vice President Joe Biden led a roundtable “cancer moonshot” discussion at Memorial Sloan Kettering

Decoder

What Are Exceptional Responders?

When a clinical trial of a new drug fails because most patients don’t respond, progress can still be made by analyzing the tumors of the rare patients who benefit.

Exceptional responders of new drugs in clinical trials.

In the Clinic

Report Highlights Advances Made at MSK That Are Changing Patients’ Lives

An annual report from an influential cancer group highlights three MSK studies that have advanced cancer research.

New treatments developed at MSK focus on both common and rare cancers.

Finding

Immunotherapy Shows Promise for Treating Solid Tumors in the Chest

A study in mouse models suggests how modified T cells may be used to treat tumors in the area just outside the lungs.

Michel Sadelain and Prasad Adusumilli